Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neoplasms, Colorectal: early-phase trial registry
1 of 4 indexed Neoplasms, Colorectal trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Neoplasms, Colorectal: 4 US clinical trials tracked, 1 recruiting.
Neoplasms, Colorectal is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is GlaxoSmithKline, running 2 of these trials.
Enrollment posture brief
Registry condition neoplasms-colorectal
OPEN 1 | RECR 25% | LATE 0 | EARLY 4 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Neoplasms, Colorectal lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neoplasms, Colorectal on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neoplasms, Colorectal is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
GlaxoSmithKline
NCT07213609
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
GlaxoSmithKline
NCT06710847
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana
NCT03428958
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Daiichi Sankyo
NCT00967616
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Neoplasms, Colorectal records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neoplasms, Colorectal trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neoplasms, Colorectal page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Neoplasms, Colorectal trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- GlaxoSmithKline sponsors the most Neoplasms, Colorectal trials on record, review their full trial history before evaluating a specific study. See GlaxoSmithKline's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neoplasms, Colorectal condition card totals 4 registered trials; most-linked intervention NUFOX + EGFR inhibitor; top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.